Does Rallies show 13F holders for TXG?

Yes. Rallies tracks hedge fund and 13F ownership data for TXG, including fund names, share counts, latest tracked quarter, and position changes when available.

Is TXG research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TXG. It does not provide personalized investment advice.

TXG (10x Genomics, Inc. Class A Common Stock) Stock Analysis - Hedge Fund Holdings

10x Genomics, Inc. Class A Common Stock (TXG) is a publicly traded Healthcare sector company. As of May 21, 2026, TXG trades at $23.86 with a market cap of $2.72B and a P/E ratio of -137.82. TXG moved +7.58% today. Year to date, TXG is +30.90%; over the trailing twelve months it is +164.10%. Its 52-week range spans $6.78 to $26.45. Analyst consensus is buy with an average price target of $24.10. Rallies surfaces TXG's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns TXG stock?

Hedge funds tracked by Rallies that own TXG include Centerbook Partners, Orbimed Advisors, Panagora Asset, Bridgewater Associates, and Pinebridge Investments. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for 10x Genomics, Inc. Class A Common Stock.

TXG Key Metrics

Key financial metrics for TXG
Metric	Value
Price	$23.86
Market Cap	$2.72B
P/E Ratio	-137.82
EPS	$-0.17
Dividend Yield	0.00%
52-Week High	$26.45
52-Week Low	$6.78
Volume	2.61M
Avg Volume	0
Revenue (TTM)	$638.78M
Net Income	$-22.66M
Gross Margin	69.60%

Top Hedge Funds Holding TXG

Centerbook Partners holds 230.77K shares of TXG, changed +0.00% as of Dec 31, 2025.
Orbimed Advisors holds 225.20K shares of TXG, changed +465.83% as of Mar 31, 2024.
Panagora Asset holds 78.05K shares of TXG, changed +0.00% as of Jun 30, 2025.
Bridgewater Associates holds 35.10K shares of TXG, changed -80.25% as of Mar 31, 2026.
Pinebridge Investments holds 17.27K shares of TXG, changed +0.00% as of Sep 30, 2024.

Latest TXG News

10x Genomics Sees Q1 Revenue of $150.8M, Launches Atera Platform — May 7, 2026
10x Genomics Debuts Atera Platform for Whole-Transcriptome Spatial Analysis — Apr 19, 2026
PerturbAI and 10x Genomics Unveil 8 Million-Cell In Vivo CRISPR Atlas — Mar 17, 2026
10x Genomics Q4 Beats Estimates, Narrows Loss to $0.13; Shares Jump 10.5% — Feb 13, 2026
10x Genomics to Analyze 1,000 Autoimmune Cases, Establish CLIA Lab and Launch 20,000-Sample AI Oncology Project — Jan 12, 2026

Recent TXG Insider Trades

Saxonov Serge sold 5.00K (~$122.78K) on Apr 14, 2026.
Saxonov Serge sold 5.00K (~$97.61K) on Mar 24, 2026.
Saxonov Serge sold 10.00K (~$191.30K) on Mar 23, 2026.

TXG Analyst Consensus

12 analysts cover TXG: 0 strong buy, 4 buy, 8 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $24.10.

Common questions about TXG

Who owns TXG stock?: Hedge funds tracked by Rallies that own TXG include Centerbook Partners, Orbimed Advisors, Panagora Asset, Bridgewater Associates, and Pinebridge Investments. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for 10x Genomics, Inc. Class A Common Stock.
Does Rallies show 13F holders for TXG?: Yes. Rallies tracks hedge fund and 13F ownership data for TXG, including fund names, share counts, latest tracked quarter, and position changes when available.
Is TXG research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TXG. It does not provide personalized investment advice.